Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort.
Identifieur interne : 000F13 ( PubMed/Curation ); précédent : 000F12; suivant : 000F14Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort.
Auteurs : Meyha N. Swaroop [États-Unis] ; Chantal M. Ferguson ; Nora K. Horick ; Melissa N. Skolny ; Cynthia L. Miller ; Lauren S. Jammallo ; Cheryl L. Brunelle ; Jean A. O'Toole ; Steven J. Isakoff ; Michelle C. Specht ; Alphonse G. TaghianSource :
- Breast cancer research and treatment [ 1573-7217 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Composés pontés (administration et posologie), Facteurs temps, Femelle, Humains, Incidence, Jeune adulte, Lymphoedème (diagnostic), Lymphoedème (épidémiologie), Lymphoedème (étiologie), Mastectomie (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Sujet âgé, Sujet âgé de 80 ans ou plus, Taxoïdes (administration et posologie), Traitement médicamenteux adjuvant (effets indésirables), Tumeurs du sein (), Tumeurs du sein (diagnostic), Tumeurs du sein (épidémiologie), Études de suivi.
- MESH :
- administration et posologie : Composés pontés, Taxoïdes.
- diagnostic : Lymphoedème, Tumeurs du sein.
- effets indésirables : Mastectomie, Protocoles de polychimiothérapie antinéoplasique, Traitement médicamenteux adjuvant.
- épidémiologie : Lymphoedème, Tumeurs du sein.
- étiologie : Lymphoedème.
- Adulte, Adulte d'âge moyen, Facteurs temps, Femelle, Humains, Incidence, Jeune adulte, Sujet âgé, Sujet âgé de 80 ans ou plus, Tumeurs du sein, Études de suivi.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols (adverse effects), Breast Neoplasms (complications), Breast Neoplasms (diagnosis), Breast Neoplasms (epidemiology), Breast Neoplasms (therapy), Bridged-Ring Compounds (administration & dosage), Chemotherapy, Adjuvant (adverse effects), Female, Follow-Up Studies, Humans, Incidence, Lymphedema (diagnosis), Lymphedema (epidemiology), Lymphedema (etiology), Mastectomy (adverse effects), Middle Aged, Taxoids (administration & dosage), Time Factors, Young Adult.
- MESH :
- chemical , administration & dosage : Bridged-Ring Compounds, Taxoids.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, Mastectomy.
- complications : Breast Neoplasms.
- diagnosis : Breast Neoplasms, Lymphedema.
- epidemiology : Breast Neoplasms, Lymphedema.
- etiology : Lymphedema.
- therapy : Breast Neoplasms.
- Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Incidence, Middle Aged, Time Factors, Young Adult.
Abstract
Taxane-based chemotherapy for the treatment of breast cancer is associated with fluid retention in the extremities; however, its association with development of breast cancer-related lymphedema is unclear. We sought to determine if adjuvant taxane-based chemotherapy increased risk of lymphedema or mild swelling of the upper extremity. 1121 patients with unilateral breast cancer were prospectively screened for lymphedema with perometer measurements. Lymphedema was defined as a relative volume change (RVC) of ≥10 % from preoperative baseline. Mild swelling was defined as RVC 5- <10 %. Clinicopathologic characteristics were obtained via medical record review. Kaplan-Meier and Cox proportional hazard analyses were performed to determine lymphedema rates and risk factors. 29 % (324/1121) of patients were treated with adjuvant taxane-based chemotherapy. The 2-year cumulative incidence of lymphedema in the overall cohort was 5.27 %. By multivariate analysis, axillary lymph node dissection (ALND) (p < 0.0001), higher body mass index (p = 0.0007), and older age at surgery (p = 0.04) were significantly associated with increased risk of lymphedema; however, taxane chemotherapy was not significant when compared to no chemotherapy and non-taxane chemotherapy (HR 1.14, p = 0.62; HR 1.56, p = 0.40, respectively). Chemotherapy with docetaxel was significantly associated with mild swelling on multivariate analysis in comparison to both no chemotherapy and non-taxane chemotherapy groups (HR 1.63, p = 0.0098; HR 2.15, p = 0.02, respectively). Patients who receive taxane-based chemotherapy are not at an increased risk of lymphedema compared to patients receiving no chemotherapy or non-taxane adjuvant chemotherapy. Those treated with docetaxel may experience mild swelling, but this does not translate into subsequent lymphedema.
DOI: 10.1007/s10549-015-3408-1
PubMed: 25940996
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000F13
Links to Exploration step
pubmed:25940996Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort.</title><author><name sortKey="Swaroop, Meyha N" sort="Swaroop, Meyha N" uniqKey="Swaroop M" first="Meyha N" last="Swaroop">Meyha N. Swaroop</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, Boston, MA, 02114, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, Boston, MA, 02114</wicri:regionArea></affiliation></author><author><name sortKey="Ferguson, Chantal M" sort="Ferguson, Chantal M" uniqKey="Ferguson C" first="Chantal M" last="Ferguson">Chantal M. Ferguson</name></author><author><name sortKey="Horick, Nora K" sort="Horick, Nora K" uniqKey="Horick N" first="Nora K" last="Horick">Nora K. Horick</name></author><author><name sortKey="Skolny, Melissa N" sort="Skolny, Melissa N" uniqKey="Skolny M" first="Melissa N" last="Skolny">Melissa N. Skolny</name></author><author><name sortKey="Miller, Cynthia L" sort="Miller, Cynthia L" uniqKey="Miller C" first="Cynthia L" last="Miller">Cynthia L. Miller</name></author><author><name sortKey="Jammallo, Lauren S" sort="Jammallo, Lauren S" uniqKey="Jammallo L" first="Lauren S" last="Jammallo">Lauren S. Jammallo</name></author><author><name sortKey="Brunelle, Cheryl L" sort="Brunelle, Cheryl L" uniqKey="Brunelle C" first="Cheryl L" last="Brunelle">Cheryl L. Brunelle</name></author><author><name sortKey="O Toole, Jean A" sort="O Toole, Jean A" uniqKey="O Toole J" first="Jean A" last="O'Toole">Jean A. O'Toole</name></author><author><name sortKey="Isakoff, Steven J" sort="Isakoff, Steven J" uniqKey="Isakoff S" first="Steven J" last="Isakoff">Steven J. Isakoff</name></author><author><name sortKey="Specht, Michelle C" sort="Specht, Michelle C" uniqKey="Specht M" first="Michelle C" last="Specht">Michelle C. Specht</name></author><author><name sortKey="Taghian, Alphonse G" sort="Taghian, Alphonse G" uniqKey="Taghian A" first="Alphonse G" last="Taghian">Alphonse G. Taghian</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25940996</idno><idno type="pmid">25940996</idno><idno type="doi">10.1007/s10549-015-3408-1</idno><idno type="wicri:Area/PubMed/Corpus">000F13</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F13</idno><idno type="wicri:Area/PubMed/Curation">000F13</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F13</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort.</title><author><name sortKey="Swaroop, Meyha N" sort="Swaroop, Meyha N" uniqKey="Swaroop M" first="Meyha N" last="Swaroop">Meyha N. Swaroop</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, Boston, MA, 02114, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, Boston, MA, 02114</wicri:regionArea></affiliation></author><author><name sortKey="Ferguson, Chantal M" sort="Ferguson, Chantal M" uniqKey="Ferguson C" first="Chantal M" last="Ferguson">Chantal M. Ferguson</name></author><author><name sortKey="Horick, Nora K" sort="Horick, Nora K" uniqKey="Horick N" first="Nora K" last="Horick">Nora K. Horick</name></author><author><name sortKey="Skolny, Melissa N" sort="Skolny, Melissa N" uniqKey="Skolny M" first="Melissa N" last="Skolny">Melissa N. Skolny</name></author><author><name sortKey="Miller, Cynthia L" sort="Miller, Cynthia L" uniqKey="Miller C" first="Cynthia L" last="Miller">Cynthia L. Miller</name></author><author><name sortKey="Jammallo, Lauren S" sort="Jammallo, Lauren S" uniqKey="Jammallo L" first="Lauren S" last="Jammallo">Lauren S. Jammallo</name></author><author><name sortKey="Brunelle, Cheryl L" sort="Brunelle, Cheryl L" uniqKey="Brunelle C" first="Cheryl L" last="Brunelle">Cheryl L. Brunelle</name></author><author><name sortKey="O Toole, Jean A" sort="O Toole, Jean A" uniqKey="O Toole J" first="Jean A" last="O'Toole">Jean A. O'Toole</name></author><author><name sortKey="Isakoff, Steven J" sort="Isakoff, Steven J" uniqKey="Isakoff S" first="Steven J" last="Isakoff">Steven J. Isakoff</name></author><author><name sortKey="Specht, Michelle C" sort="Specht, Michelle C" uniqKey="Specht M" first="Michelle C" last="Specht">Michelle C. Specht</name></author><author><name sortKey="Taghian, Alphonse G" sort="Taghian, Alphonse G" uniqKey="Taghian A" first="Alphonse G" last="Taghian">Alphonse G. Taghian</name></author></analytic><series><title level="j">Breast cancer research and treatment</title><idno type="eISSN">1573-7217</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Breast Neoplasms (complications)</term><term>Breast Neoplasms (diagnosis)</term><term>Breast Neoplasms (epidemiology)</term><term>Breast Neoplasms (therapy)</term><term>Bridged-Ring Compounds (administration & dosage)</term><term>Chemotherapy, Adjuvant (adverse effects)</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Incidence</term><term>Lymphedema (diagnosis)</term><term>Lymphedema (epidemiology)</term><term>Lymphedema (etiology)</term><term>Mastectomy (adverse effects)</term><term>Middle Aged</term><term>Taxoids (administration & dosage)</term><term>Time Factors</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Composés pontés (administration et posologie)</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Incidence</term><term>Jeune adulte</term><term>Lymphoedème (diagnostic)</term><term>Lymphoedème (épidémiologie)</term><term>Lymphoedème (étiologie)</term><term>Mastectomie (effets indésirables)</term><term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Taxoïdes (administration et posologie)</term><term>Traitement médicamenteux adjuvant (effets indésirables)</term><term>Tumeurs du sein ()</term><term>Tumeurs du sein (diagnostic)</term><term>Tumeurs du sein (épidémiologie)</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Bridged-Ring Compounds</term><term>Taxoids</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Composés pontés</term><term>Taxoïdes</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Chemotherapy, Adjuvant</term><term>Mastectomy</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Breast Neoplasms</term><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Lymphoedème</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Mastectomie</term><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Traitement médicamenteux adjuvant</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Breast Neoplasms</term><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Lymphoedème</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Lymphoedème</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Incidence</term><term>Middle Aged</term><term>Time Factors</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Incidence</term><term>Jeune adulte</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Tumeurs du sein</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Taxane-based chemotherapy for the treatment of breast cancer is associated with fluid retention in the extremities; however, its association with development of breast cancer-related lymphedema is unclear. We sought to determine if adjuvant taxane-based chemotherapy increased risk of lymphedema or mild swelling of the upper extremity. 1121 patients with unilateral breast cancer were prospectively screened for lymphedema with perometer measurements. Lymphedema was defined as a relative volume change (RVC) of ≥10 % from preoperative baseline. Mild swelling was defined as RVC 5- <10 %. Clinicopathologic characteristics were obtained via medical record review. Kaplan-Meier and Cox proportional hazard analyses were performed to determine lymphedema rates and risk factors. 29 % (324/1121) of patients were treated with adjuvant taxane-based chemotherapy. The 2-year cumulative incidence of lymphedema in the overall cohort was 5.27 %. By multivariate analysis, axillary lymph node dissection (ALND) (p < 0.0001), higher body mass index (p = 0.0007), and older age at surgery (p = 0.04) were significantly associated with increased risk of lymphedema; however, taxane chemotherapy was not significant when compared to no chemotherapy and non-taxane chemotherapy (HR 1.14, p = 0.62; HR 1.56, p = 0.40, respectively). Chemotherapy with docetaxel was significantly associated with mild swelling on multivariate analysis in comparison to both no chemotherapy and non-taxane chemotherapy groups (HR 1.63, p = 0.0098; HR 2.15, p = 0.02, respectively). Patients who receive taxane-based chemotherapy are not at an increased risk of lymphedema compared to patients receiving no chemotherapy or non-taxane adjuvant chemotherapy. Those treated with docetaxel may experience mild swelling, but this does not translate into subsequent lymphedema.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25940996</PMID><DateCreated><Year>2015</Year><Month>05</Month><Day>15</Day></DateCreated><DateCompleted><Year>2016</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-7217</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Breast cancer research and treatment</Title><ISOAbbreviation>Breast Cancer Res. Treat.</ISOAbbreviation></Journal><ArticleTitle>Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort.</ArticleTitle><Pagination><MedlinePgn>393-403</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-015-3408-1</ELocationID><Abstract><AbstractText>Taxane-based chemotherapy for the treatment of breast cancer is associated with fluid retention in the extremities; however, its association with development of breast cancer-related lymphedema is unclear. We sought to determine if adjuvant taxane-based chemotherapy increased risk of lymphedema or mild swelling of the upper extremity. 1121 patients with unilateral breast cancer were prospectively screened for lymphedema with perometer measurements. Lymphedema was defined as a relative volume change (RVC) of ≥10 % from preoperative baseline. Mild swelling was defined as RVC 5- <10 %. Clinicopathologic characteristics were obtained via medical record review. Kaplan-Meier and Cox proportional hazard analyses were performed to determine lymphedema rates and risk factors. 29 % (324/1121) of patients were treated with adjuvant taxane-based chemotherapy. The 2-year cumulative incidence of lymphedema in the overall cohort was 5.27 %. By multivariate analysis, axillary lymph node dissection (ALND) (p < 0.0001), higher body mass index (p = 0.0007), and older age at surgery (p = 0.04) were significantly associated with increased risk of lymphedema; however, taxane chemotherapy was not significant when compared to no chemotherapy and non-taxane chemotherapy (HR 1.14, p = 0.62; HR 1.56, p = 0.40, respectively). Chemotherapy with docetaxel was significantly associated with mild swelling on multivariate analysis in comparison to both no chemotherapy and non-taxane chemotherapy groups (HR 1.63, p = 0.0098; HR 2.15, p = 0.02, respectively). Patients who receive taxane-based chemotherapy are not at an increased risk of lymphedema compared to patients receiving no chemotherapy or non-taxane adjuvant chemotherapy. Those treated with docetaxel may experience mild swelling, but this does not translate into subsequent lymphedema.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Swaroop</LastName><ForeName>Meyha N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferguson</LastName><ForeName>Chantal M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Horick</LastName><ForeName>Nora K</ForeName><Initials>NK</Initials></Author><Author ValidYN="Y"><LastName>Skolny</LastName><ForeName>Melissa N</ForeName><Initials>MN</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Cynthia L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Jammallo</LastName><ForeName>Lauren S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Brunelle</LastName><ForeName>Cheryl L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>O'Toole</LastName><ForeName>Jean A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Isakoff</LastName><ForeName>Steven J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Specht</LastName><ForeName>Michelle C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Taghian</LastName><ForeName>Alphonse G</ForeName><Initials>AG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 CA089393</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA139118</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50CA089393</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01CA139118</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>05</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Breast Cancer Res Treat</MedlineTA><NlmUniqueID>8111104</NlmUniqueID><ISSNLinking>0167-6806</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001952">Bridged-Ring Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D043823">Taxoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>1605-68-1</RegistryNumber><NameOfSubstance UI="C080625">taxane</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Lymphology. 2007 Mar;40(1):26-34</RefSource><PMID Version="1">17539462</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lymphology. 2009 Dec;42(4):161-75</RefSource><PMID Version="1">20218084</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lymphat Res Biol. 2014 Dec;12(4):282-8</RefSource><PMID Version="1">25411764</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lymphat Res Biol. 2014 Dec;12(4):289-94</RefSource><PMID Version="1">25495384</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lymphat Res Biol. 2005;3(4):208-17</RefSource><PMID Version="1">16379589</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2012 Feb 4;379(9814):432-44</RefSource><PMID Version="1">22152853</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2012 Aug;135(1):145-52</RefSource><PMID Version="1">22710706</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast. 2010 Dec;19(6):506-15</RefSource><PMID Version="1">20561790</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Surg. 2004 Jan;187(1):69-72</RefSource><PMID Version="1">14706589</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lymphat Res Biol. 2014 Sep;12(3):197-202</RefSource><PMID Version="1">25144149</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast J. 2006 Nov-Dec;12(6):536-43</RefSource><PMID Version="1">17238983</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2008 Jun 15;112(12):2809-19</RefSource><PMID Version="1">18428212</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2007 Aug 20;25(24):3657-63</RefSource><PMID Version="1">17485711</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Jul 20;26(21):3536-42</RefSource><PMID Version="1">18640935</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lymphat Res Biol. 2009;7(2):109-12</RefSource><PMID Version="1">19534633</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2003 Mar 15;21(6):976-83</RefSource><PMID Version="1">12637460</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2011;6(11):e26946</RefSource><PMID Version="1">22069477</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Oncol. 2008;47(5):835-42</RefSource><PMID Version="1">18568481</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2013 Sep;20(9):2835-41</RefSource><PMID Version="1">23689935</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2010 Dec 2;363(23):2200-10</RefSource><PMID Version="1">21121833</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2005 Jun 2;352(22):2302-13</RefSource><PMID Version="1">15930421</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1997 Sep;15(9):3149-55</RefSource><PMID Version="1">9294478</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 May;14(6):500-15</RefSource><PMID Version="1">23540561</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Vasc Endovasc Surg. 1996 Nov;12(4):412-7</RefSource><PMID Version="1">8980428</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2013 Aug;140(3):485-94</RefSource><PMID Version="1">23912961</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2013 Nov;142(1):59-67</RefSource><PMID Version="1">24122390</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1436-43</RefSource><PMID Version="1">20605339</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Asian Pac J Cancer Prev. 2014;15(16):6535-41</RefSource><PMID Version="1">25169483</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Surg Oncol. 2006 Nov;15(3):153-65</RefSource><PMID Version="1">17187979</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Physiol Heart Circ Physiol. 2004 Aug;287(2):H963-8</RefSource><PMID Version="1">15059777</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Jan 1;26(1):44-53</RefSource><PMID Version="1">18165639</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Phys Ther. 2006 Feb;86(2):205-14</RefSource><PMID Version="1">16445334</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2005 Jun 1;23(16):3686-96</RefSource><PMID Version="1">15897552</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):775-82</RefSource><PMID Version="1">17416770</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncology. 2012;82(3):131-8</RefSource><PMID Version="1">22433221</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2011 Dec;130(3):981-91</RefSource><PMID Version="1">21761159</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2009 Jan;113(2):383-91</RefSource><PMID Version="1">18297429</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncol Nurs Forum. 2014 Sep;41(5):473-83</RefSource><PMID Version="1">25158653</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2008 Apr 17;358(16):1663-71</RefSource><PMID Version="1">18420499</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Plast Reconstr Surg. 2012 May;129(5):789e-95e</RefSource><PMID Version="1">22544109</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1095-100</RefSource><PMID Version="1">22099041</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncol Nurs Forum. 2009 Mar;36(2):185-93</RefSource><PMID Version="1">19273407</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Crit Rev Oncol Hematol. 2013 Nov;88(2):437-46</RefSource><PMID Version="1">23777977</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lymphology. 2006 Dec;39(4):193-200</RefSource><PMID Version="1">17319632</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Surg Clin North Am. 2003 Aug;83(4):943-71</RefSource><PMID Version="1">12875604</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1998 Oct;16(10):3426-32</RefSource><PMID Version="1">9779722</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer Care (Engl). 2016 Mar;25(2):269-79</RefSource><PMID Version="1">25348689</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pers Med. 2014 Aug 18;4(3):424-47</RefSource><PMID Version="1">25563360</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lymphat Res Biol. 2015 Dec;13(4):268-74</RefSource><PMID Version="1">24837643</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Support Care Cancer. 2013 Aug;21(8):2207-15</RefSource><PMID Version="1">23494582</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Eur Acad Dermatol Venereol. 2007 Sep;21(8):1131-3</RefSource><PMID Version="1">17714152</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lymphology. 1997 Jun;30(2):77-97</RefSource><PMID Version="1">9215977</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Breast Cancer. 2012 Dec;15(4):449-53</RefSource><PMID Version="1">23346175</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer. 2010 Oct;17(4):281-5</RefSource><PMID Version="1">19789952</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Apr 20;27(12):2007-14</RefSource><PMID Version="1">19289624</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):565-71</RefSource><PMID Version="1">24411624</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Nurs. 2008 Jun;17(11):1450-9</RefSource><PMID Version="1">18482142</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2013 Jan;14(1):72-80</RefSource><PMID Version="1">23246022</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2734-46</RefSource><PMID Version="1">20978176</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res. 2014;16(4):414</RefSource><PMID Version="1">25145603</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):498-503</RefSource><PMID Version="1">23541809</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Clin Pharmacol. 1997 Jun;43(6):653-8</RefSource><PMID Version="1">9205828</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Surg Oncol. 2010 Jan 1;101(1):84-91</RefSource><PMID Version="1">19924721</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2014 Nov;148(1):91-8</RefSource><PMID Version="1">25253173</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2009 Jul;16(7):1959-72</RefSource><PMID Version="1">19365624</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2012 Jun 20;30(18):2232-9</RefSource><PMID Version="1">22614988</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cochrane Database Syst Rev. 2007;(4):CD004421</RefSource><PMID Version="1">17943815</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001952" MajorTopicYN="N">Bridged-Ring Compounds</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008408" MajorTopicYN="N">Mastectomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043823" MajorTopicYN="N">Taxoids</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4432026</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>04</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>04</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25940996</ArticleId><ArticleId IdType="doi">10.1007/s10549-015-3408-1</ArticleId><ArticleId IdType="pmc">PMC4432026</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F13 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000F13 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:25940996
|texte= Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:25940996" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |